Not a good buy right now: the stock is in a strong bearish trend (SMA_200 > SMA_20 > SMA_5) and just suffered a sharp -12.5% regular-session drop.
Oversold RSI (RSI_6 ~15.4) can produce a short-lived bounce, but there is no confirming buy signal (AI Stock Picker/SwingMax both absent) and the broader trend remains down.
Options market is extremely illiquid (0 volume) with distorted-looking IV, so it’s not providing reliable bullish confirmation.
Fundamentals remain weak: tiny revenue base and worsening losses in the latest reported quarter (2025/Q2).
Technical Analysis
Trend: Bearish structure with moving averages stacked negatively (SMA_200 > SMA_20 > SMA_5), suggesting rallies are likely to face selling pressure.
Momentum: MACD histogram is above 0 (0.00651) but positively contracting—reads more like a fading counter-trend uptick than a durable reversal.
Overbought/oversold: RSI_6 at ~15.4 is deeply oversold, increasing odds of a near-term technical bounce, but oversold alone is not a buy trigger in a downtrend.
Key levels: Price (~0.919) is sitting on S1 (0.919). A clean break below risks a move toward S2 (0.86). Upside hurdles: Pivot 1.014 then R1 1.11.
Open interest is small and skewed toward calls (call OI 81 vs put OI 3), but today’s options volume is 0—sentiment read is low-confidence due to illiquidity.
Implied volatility metrics are extreme (IV_30d ~926.64%; IV rank ~120), which often happens in thinly traded microcaps; it can reflect pricing distortions more than actionable sentiment.
With no volume and very limited OI, options are not confirming a bullish turn despite the oversold stock condition.
Gross margin: 67.19% (down -2.78% YoY) — still high but trending weaker.
Overall: operating performance does not yet support a durable rerating; the equity is trading more like a high-risk speculative vehicle than a fundamentals-backed compounder.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data was provided, so a recent Wall Street trend cannot be confirmed.
Typical Wall Street-style pros (if covered): optionality on autonomy/ADAS adoption and potential partnership wins.
Typical cons: microcap liquidity, inconsistent commercialization progress, and persistent losses; without clear catalyst/coverage, conviction tends to be low.
Influential/political trading: No recent congress trading data available; hedge fund and insider trends are neutral in the provided dataset.
Wall Street analysts forecast FRSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FRSX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast FRSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FRSX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
